Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

NLTX | Neoleukin Therapeutics Inc

Index	-	P/E	-	EPS (ttm)	-0.85	Insider Own	20.78%	Shs Outstand	42.65M	Perf Week	-9.35%
Market Cap	153.63M	Forward P/E	-	EPS next Y	-	Insider Trans	33.21%	Shs Float	34.87M	Perf Month	-3.83%
Income	-42.81M	PEG	-	EPS next Q	-0.15	Inst Own	44.47%	Short Float / Ratio	0.07% / 0.40	Perf Quarter	-11.08%
Sales	0.00M	P/S	-	EPS this Y	69.23%	Inst Trans	-12.19%	Short Interest	0.02M	Perf Half Y	10.11%
Book/sh	1.81	P/B	1.93	EPS next Y	-	ROA	-37.06%	Target Price	7.50	Perf Year	-5.68%
Cash/sh	1.86	P/C	1.87	EPS next 5Y	-	ROE	-43.62%	52W Range	1.88 - 4.70	Perf YTD	37.13%
Dividend	-	P/FCF	-	EPS past 5Y	13.40%	ROI	-48.03%	52W High	-25.74%	Beta	1.17
Dividend %	-	Quick Ratio	17.17	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	86.13%	ATR	0.26
Employees	56	Current Ratio	17.17	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	42.76	Volatility	8.00% 7.30%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	86.95%	Profit Margin	-	Rel Volume	1.09	Prev Close	3.44
Shortable	No	LT Debt/Eq	0.12	Earnings	-	Payout	-	Avg Volume	59.47K	Price	3.49
Recom	3.00	SMA20	-6.66%	SMA50	-2.81%	SMA200	1.29%	Volume	29,527	Change	1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-21	Resumed	Piper Sandler	Overweight	$30
Jan-06-21	Initiated	Stifel	Buy	$18
Sep-23-20	Initiated	Robert W. Baird	Outperform	$25
Jun-18-20	Initiated	Mizuho	Buy	$21
Apr-13-20	Initiated	H.C. Wainwright	Buy	$22
Mar-16-20	Initiated	BofA/Merrill	Buy	$18
Mar-12-20	Initiated	Canaccord Genuity	Buy	$20
Feb-18-20	Initiated	Guggenheim	Buy	$20
Jan-10-20	Initiated	Piper Sandler	Overweight	$20

Sep-22-23 08:00AM	Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Aug-17-23 09:02PM	BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc (GuruFocus.com)
Jul-27-23 09:34PM	Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc (GuruFocus.com)
Jul-18-23 06:30AM	Neurogene and Neoleukin Announce Definitive Merger Agreement (GlobeNewswire) -20.11%
May-09-23 03:28PM	Neoleukin: Q1 Earnings Snapshot (AP Finance)
10:42AM	Loading…
Mar-10-23 10:42AM	Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan (Zacks) -12.49%
10:13AM	Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation (Simply Wall St.)
Mar-09-23 10:41AM	Neoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 Months (Benzinga) +35.80%
Mar-08-23 05:00PM	Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition (GlobeNewswire)
Dec-12-22 01:00PM	Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +7.12%
Nov-16-22 10:39AM	Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down (Zacks) -5.27%
Nov-15-22 10:30AM	Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength (Benzinga) -19.86%
Nov-14-22 04:03PM	Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update (GlobeNewswire)
Nov-03-22 09:05AM	Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-01-22 08:53AM	We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate (Simply Wall St.)
04:02PM	Loading…
Aug-09-22 04:02PM	Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update (GlobeNewswire) -7.96%
Aug-03-22 08:00AM	Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire)
Jul-27-22 08:00AM	Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022 (GlobeNewswire)
Jul-04-22 06:42AM	Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) insider upped their holding by 6.7% earlier this year (Simply Wall St.)
May-16-22 08:00AM	Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab) (GlobeNewswire) +11.21%
May-09-22 04:05PM	Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update (GlobeNewswire) -7.32%
May-05-22 08:00AM	Neoleukin Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.76%
Apr-24-22 08:38AM	We Think Neoleukin Therapeutics (NASDAQ:NLTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-13-22 10:00AM	Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -11.25%
Apr-07-22 08:00AM	Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference (GlobeNewswire)
Mar-15-22 08:00AM	Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel (GlobeNewswire)
Mar-08-22 04:01PM	Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-01-22 04:03PM	Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update (GlobeNewswire)
Feb-22-22 08:00AM	Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022 (GlobeNewswire)
Feb-03-22 08:00AM	Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) -5.93%
09:15AM	Loading…
Jan-24-22 09:15AM	As Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) drops to US$138m market cap, insiders might rethink their US$1.4m stock purchase earlier this year (Simply Wall St.) +6.46%
Jan-10-22 08:00AM	Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab) (GlobeNewswire)
06:00AM	Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Dec-11-21 05:30PM	Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021) (GlobeNewswire)
Nov-12-21 07:05AM	Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancers 36th Annual Meeting (SITC 2021) (GlobeNewswire)
Nov-09-21 08:00AM	Neoleukin Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-04-21 04:05PM	Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire)
Oct-25-21 12:57PM	Here's What Neoleukin Therapeutics, Inc.'s (NASDAQ:NLTX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Oct-01-21 09:08AM	Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancers 36th Annual Meeting (SITC 2021) (GlobeNewswire)
Sep-29-21 08:00AM	Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern (GlobeNewswire)
Sep-27-21 11:55AM	10 Cheap Pharmaceutical Stocks to Watch (Insider Monkey) +5.91%
Sep-09-21 08:00AM	Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research (GlobeNewswire)
Sep-07-21 08:00AM	Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 04:05PM	Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update (GlobeNewswire) +12.78%
Jun-08-21 01:56AM	Insider Buying: The Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) CEO, President & Director Just Bought 2.3% More Shares (Simply Wall St.) +6.82%
May-26-21 08:00AM	Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-17-21 10:29AM	Is Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Popular Amongst Insiders? (Simply Wall St.)
May-12-21 08:00AM	Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -6.32%
May-05-21 08:00AM	Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial (GlobeNewswire)
May-04-21 08:00AM	Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference (GlobeNewswire) -10.94%
May-03-21 08:00AM	Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer (GlobeNewswire)
Apr-26-21 10:19AM	Neoleukin's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors (Benzinga) +5.99%
07:00AM	Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States (GlobeNewswire)
Apr-17-21 09:20AM	10 Cheap Pharmaceutical Stocks For 2021 (Insider Monkey)
Mar-26-21 08:00PM	Neoleukin Therapeutics, Inc. (NLTX) Q4 2020 Earnings Call Transcript (Motley Fool)
Mar-25-21 04:00PM	Neoleukin Therapeutics Announces Year End 2020 Financial Results (GlobeNewswire)
02:30PM	Neoleukin Therapeutics Inc to Host Earnings Call (ACCESSWIRE)
Mar-18-21 08:00AM	Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021 (GlobeNewswire)
Mar-02-21 08:00AM	Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference (GlobeNewswire)
Feb-05-21 08:00AM	Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days (GlobeNewswire) +7.59%
Jan-28-21 11:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX (ACCESSWIRE)
Jan-25-21 11:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX (Newsfile)
02:49PM	SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC (Newsfile)
Jan-23-21 11:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX (ACCESSWIRE)
Jan-20-21 11:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX (Newsfile)
Jan-14-21 11:25AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) Investigation (ACCESSWIRE)
Jan-08-21 12:49PM	Why Neoleukin Therapeutics Stock Is Down Today (Motley Fool) -10.96%
08:37AM	U.S. FDA puts early-stage trial of Neoleukin potential cancer treatment on hold (Reuters)
08:00AM	Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201 (GlobeNewswire)
Jan-07-21 08:00AM	Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-20 08:00AM	Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer (GlobeNewswire)
Nov-23-20 08:00AM	Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-18-20 01:59AM	Did Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Insiders Buy Up More Shares? (Simply Wall St.)
Nov-11-20 08:00AM	Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference (GlobeNewswire)
Nov-10-20 08:00AM	Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancers 35th Anniversary Annual Meeting (SITC 2020) (GlobeNewswire)
Nov-09-20 08:00AM	Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update (GlobeNewswire)
Nov-05-20 02:00PM	Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo (GlobeNewswire)
Oct-20-20 08:00AM	Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel (GlobeNewswire) -5.45%
Oct-14-20 05:05PM	Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancers 35th Anniversary Annual Meeting (SITC 2020) (GlobeNewswire)
Oct-13-20 03:06PM	Should I Avoid Neoleukin Therapeutics, Inc. (NLTX)? (Insider Monkey)
Sep-23-20 09:33AM	Benzinga's Top Upgrades, Downgrades For September 23, 2020 (Benzinga)
Sep-15-20 01:11PM	Top Pharmaceutical Stocks for Q4 2020 (Investopedia)
Sep-10-20 08:00AM	Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors (GlobeNewswire)
Sep-09-20 08:00AM	Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference (GlobeNewswire)
Aug-20-20 01:26PM	What Type Of Shareholders Own The Most Number of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares? (Simply Wall St.)
Aug-19-20 12:00PM	Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.40%
Aug-12-20 04:01PM	Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update (GlobeNewswire)
Aug-06-20 08:00AM	Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference (GlobeNewswire)
Aug-05-20 08:00AM	Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020 (GlobeNewswire)
Aug-03-20 10:50AM	Were Hedge Funds Right About Neoleukin Therapeutics, Inc. (NLTX)? (Insider Monkey) +6.40%
Jul-15-20 07:21AM	Is Neoleukin Therapeutics a Buy? (Motley Fool) +5.71%
Jul-07-20 07:35AM	Is It Too Late to Buy These 3 Pharmaceutical Stocks? (Motley Fool)
Jul-03-20 12:00PM	Neoleukin (NLTX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jul-02-20 12:54PM	Here's Why Neoleukin Therapeutics Dropped Today (Motley Fool) -17.70%
09:00AM	Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering (GlobeNewswire)
Jul-01-20 04:01PM	Neoleukin Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Jun-24-20 10:24AM	Neoleukin Therapeutics (NLTX) Looks Good: Stock Adds 9.4% in Session (Zacks)
Jun-22-20 09:05AM	Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II (GlobeNewswire) -7.97%
Jun-19-20 12:49PM	Hedge Funds Have Never Been More Bullish On Neoleukin Therapeutics, Inc. (NLTX) (Insider Monkey) +10.86%
Jun-15-20 08:00AM	Neoleukin Therapeutics to Host Investor R&D Showcase Highlighting De Novo Protein Therapeutics (GlobeNewswire)

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	Director	Aug 17	Buy	0.69	166,942	115,617	5,612,949	Aug 17 05:08 PM
BAKER BROS. ADVISORS LP	Director	Aug 16	Buy	0.68	229,600	156,254	5,458,724	Aug 17 05:08 PM
BAKER BROS. ADVISORS LP	Director	Aug 15	Buy	0.63	1,888,800	1,191,616	5,246,614	Aug 17 05:08 PM
Smith Sean Michael	Interim CFO, Prin Acct Off	Aug 11	Sale	0.62	1,323	818	21,637	Aug 14 04:06 PM
Smith Sean Michael	Interim CFO, Prin Acct Off	Aug 10	Option Exercise	0.00	5,000	0	22,960	Aug 14 04:06 PM
Patel Priti	Former Chief Medical Officer	Apr 03	Sale	0.69	3,769	2,608	37,313	Apr 04 08:51 PM
Patel Priti	Former Chief Medical Officer	Mar 31	Option Exercise	0.00	10,000	0	41,082	Apr 04 08:51 PM
Patel Priti	Chief Medical Officer	Feb 02	Sale	0.60	14,380	8,588	31,082	Feb 03 04:32 PM
Smith Sean Michael	Principal Accounting Officer	Feb 02	Sale	0.60	3,316	1,980	15,960	Feb 03 04:33 PM
Patel Priti	Chief Medical Officer	Feb 01	Option Exercise	0.00	35,000	0	45,462	Feb 03 04:32 PM
Smith Sean Michael	Principal Accounting Officer	Feb 01	Option Exercise	0.00	12,500	0	19,276	Feb 03 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NLTX | Neoleukin Therapeutics Inc

Upgrade your FINVIZ experience